Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 16/20 | 0.51 |
| ▸ | CNR2 | P34972 | 3/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4012889 | 0.86 | CNR1 (0.47) | CNR1CNR2 | |
| SCHEMBL3924890 | 0.86 | CNR1 (0.52) | CNR1CNR2EGLN1NPC1RAB9A | |
| SCHEMBL3915821 | 0.86 | CNR1 (0.52) | CNR1CNR2EGLN1NPC1RAB9A | |
| SCHEMBL4011940 | 0.83 | CNR1 (0.50) | CNR1CNR2 | |
| SCHEMBL4012691 | 0.83 | CNR1 (0.54) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL4010097 | 0.82 | CNR1 (0.44) | CNR1CNR2EGLN1NPC1RAB9A | |
| SCHEMBL4014934 | 0.82 | CNR1 (0.51) | CNR1CNR2 | |
| SCHEMBL4013119 | 0.82 | CNR1 (0.53) | CNR1CNR2NPC1RAB9A | |
| SCHEMBL4162485 | 0.81 | CNR1 (0.48) | CNR1CNR2 | |
| SCHEMBL4013487 | 0.81 | CNR1 (0.50) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074096-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008040651-A1 | 3-PYRIDINECARBOXAMIDE AND 2-PYRAZINECARBOXAMIDE DERIVATIVES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-10 | — | — | WO | disclosed |